UBS Group
VIVO

UBS Group’s Meridian Bioscience Inc VIVO Stock Holding History

UBS Group’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-50,739
Closed -$1.69M – 11451
2022
Q4 		$1.69M Buy
50,739
+20,672
+69% +$666K ﹤0.01% 3566
2022
Q3 		$948K Buy
30,067
+23,059
+329% +$747K ﹤0.01% 3794
2022
Q2 		$213K Sell
7,008
-216,759
-97% -$5.86M ﹤0.01% 4858
2022
Q1 		$5.81M Sell
223,767
-3,481
-2% -$82.8K ﹤0.01% 2399
2021
Q4 		$4.64M Buy
227,248
+220,942
+3,504% +$4.24M ﹤0.01% 2905
2021
Q3 		$122K Sell
6,306
-1,708
-21% -$34K ﹤0.01% 5689
2021
Q2 		$178K Sell
8,014
-27,038
-77% -$574K ﹤0.01% 5446
2021
Q1 		$920K Buy
35,052
+1,376
+4% +$32.7K ﹤0.01% 4348
2020
Q4 		$630K Buy
33,676
+4,770
+17% +$89.1K ﹤0.01% 4414
2020
Q3 		$491K Sell
28,906
-3,686
-11% -$71.6K ﹤0.01% 4217
2020
Q2 		$759K Sell
32,592
-985
-3% -$14.3K ﹤0.01% 3754
2020
Q1 		$282K Sell
33,577
-23,389
-41% -$197K ﹤0.01% 4446
2019
Q4 		$556K Buy
56,966
+18,448
+48% +$173K ﹤0.01% 4749
2019
Q3 		$365K Buy
38,518
+21,680
+129% +$228K ﹤0.01% 4802
2019
Q2 		$200K Buy
16,838
+9,253
+122% +$111K ﹤0.01% 4915
2019
Q1 		$134K Sell
7,585
-16,206
-68% -$270K ﹤0.01% 4870
2018
Q4 		$413K Buy
23,791
+4,547
+24% +$77.5K ﹤0.01% 4415
2018
Q3 		$287K Buy
19,244
+5,837
+44% +$90.5K ﹤0.01% 4792
2018
Q2 		$213K Buy
13,407
+4,182
+45% +$62.4K ﹤0.01% 4895
2018
Q1 		$131K Sell
9,225
-2,907
-24% -$43K ﹤0.01% 5055
2017
Q4 		$170K Sell
12,132
-4,493
-27% -$65.8K ﹤0.01% 5034
2017
Q3 		$238K Sell
16,625
-477,119
-97% -$6.82M ﹤0.01% 4726
2017
Q2 		$7.78M Buy
493,744
+476,845
+2,822% +$6.87M ﹤0.01% 1752
2017
Q1 		$233K Sell
16,899
-2,634
-13% -$36.8K ﹤0.01% 4565
2016
Q4 		$345K Buy
19,533
+6,512
+50% +$114K ﹤0.01% 4388
2016
Q3 		$251K Sell
13,021
-6,246
-32% -$122K ﹤0.01% 4389
2016
Q2 		$375K Buy
19,267
+153
+0.8% +$3K ﹤0.01% 4115
2016
Q1 		$394K Buy
19,114
+6,077
+47% +$120K ﹤0.01% 3953
2015
Q4 		$268K Sell
13,037
-3,927
-23% -$75.3K ﹤0.01% 4450
2015
Q3 		$290K Sell
16,964
-4,676
-22% -$85.5K ﹤0.01% 4342
2015
Q2 		$404K Sell
21,640
-76,275
-78% -$1.41M ﹤0.01% 4296
2015
Q1 		$1.87M Buy
97,915
+14,806
+18% +$274K ﹤0.01% 2993
2014
Q4 		$1.37M Buy
+83,109
New +$1.43M ﹤0.01% 3297

Other funds holding VIVO

BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

UBS Group's VIVO Position: Q1 2023 in Review

UBS Group sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 50,739 shares — an estimated $1.69M sold.

UBS Group first reported a position in VIVO in Q4 2014 and held it in 33 quarters. The position peaked at $7.78M in Q2 2017. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.

  • UBS Group reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
  • UBS Group sold 50,739 Meridian Bioscience Inc shares in Q1 2023, an estimated $1.69M.
  • UBS Group first reported a position in Meridian Bioscience Inc in Q4 2014 and held it in 33 quarters.
  • UBS Group's Meridian Bioscience Inc position peaked at $7.78M in Q2 2017.
  • 2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.

Based on UBS Group's 13F filing for Q1 2023, filed 12 May 2023.